N4 Pharma PLC Result of AGM (1932V)

TIDMN4P

RNS Number : 1932V

N4 Pharma PLC

03 April 2023

3 April 2023

N4 Pharma plc

("N4 Pharma" or the "Company")

Result of Annual General Meeting

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed.

 
                                                        Against                Witheld 
 Resolution             For          For%     Against    %        Total         votes* 
 Ordinary Resolution 
  1 - To receive 
  the annual report 
  and audited 
  accounts for 
  the year ended 
  31 December 
  2022                  20,267,523   99.37%   127,579   0.63%     20,395,102   19,729 
                       -----------  -------  --------  --------  -----------  -------- 
 Ordinary Resolution 
  2 - To re-elect 
  John Chiplin 
  as a Director 
  of the Company        20,004,322   98.08%   390,780   1.92%     20,395,102   19,729 
                       -----------  -------  --------  --------  -----------  -------- 
 Ordinary Resolution 
  3 - To re-elect 
  Luke Cairns 
  as a Director 
  of the Company        20,165,927   98.88%   229,175   1.12%     20,395,102   19,729 
                       -----------  -------  --------  --------  -----------  -------- 
 Ordinary Resolution 
  4 - To re-elect 
  Chris Britten 
  as a Director 
  of the Company        20,004,322   98.87%   229,175   1.13%     20,233,497   181,334 
                       -----------  -------  --------  --------  -----------  -------- 
 Ordinary Resolution 
  5 - To re-appoint 
  Saffery Champness 
  LLP as the Company 
  s auditor and 
  to authorise 
  the Directors 
  to determine 
  their remuneration    20,037,518   98.25%   356,384   1.75%     20,393,902   20,929 
                       -----------  -------  --------  --------  -----------  -------- 
 Ordinary Resolution 
  6 - To authorise 
  the Directors 
  to allot shares       19,996,465   98.36%   333,237   1.64%     20,329,702   85,129 
                       -----------  -------  --------  --------  -----------  -------- 
 Special Resolution 
  7 - To disapply 
  pre-emption 
  rights                20,003,065   98.39%   326,437   1.61%     20,329,502   85,329 
                       -----------  -------  --------  --------  -----------  -------- 
 

*Please note a vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

Enquiries:

 
 N4 Pharma plc 
 Nigel Theobald, CEO                           Via IFC Advisory 
 Luke Cairns, Executive Director 
 
 SP Angel Corporate Finance LLP                Tel: [phone] 
                                                0470 
 Nominated Adviser and Joint Broker 
 Matthew Johnson/Kasia Brzozowska (Corporate 
  Finance) 
 Vadim Alexandre/Abigail Wayne/Rob Rees 
  (Corporate Broking) 
 
 Turner Pope Investments (TPI) Limited         Tel: [phone] 
                                                0050 
 Joint Broker 
 Andy Thacker 
  James Pope 
 
 IFC Advisory Ltd                              Tel: [phone] 
                                                6630 
 Financial PR 
 Graham Herring 
 Zach Cohen 
 
 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through preclinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBXGDSIGGDGXX

(END) Dow Jones Newswires

April 03, 2023 09:11 ET (13:11 GMT)